Uncovering Biomarker and Diagnostic Opportunities in Immune and Inflammatory Diseases
Decision Resources
August 21, 2009 28 Pages - SKU: DECR2427944
|
|
Introduction
Despite the robust drug market for immune and infl ammatory diseases and their high prevalence, diagnostics associated
with these diseases do not constitute a large marketplace. Although researchers are working to discover
biomarkers, associate genes with disease, and develop diagnostics, a healthy commercial market for diagnostic
technologies and biomarker-based products in immune and infl ammatory therapeutic areas is still years away.
The present opportunity is to identify biomarkers with high levels of sensitivity and specificity that can be validated
for use in drug or diagnostic development and, particularly, in disease management to guide and target the
use of therapies.
Get the Answers You Need to Shape Your Strategy
- Current ability to diagnose immune/infl ammatory diseases accurately and quickly is limited. What are the
common diagnostic approaches? Which indications exhibit the highest level of unmet need in terms of
diagnostics? How can diagnostics/biomarker developers tap the opportunities that current shortcomings
present?
- Biomarkers do not currently play a large role in clinical practice, but their potential utility is apparent. What
do thought leaders say about biomarkers for immune/infl ammatory diseases? How can biomarkers
target and track therapies? What developments of note are under way?
- Large companies are interested in using biomarkers or diagnostics developed by smaller companies to target
patients who are candidates for their immune/infl ammatory pipeline drugs. What proportion of the companies
involved in these deals are private/venture-backed companies, small-cap companies, or academic
institutions? How many of the 52 companies we analyze relied on backing from large-cap pharmaceutical
companies?
Scope
- Indications: systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), juvenile idiopathic
arthritis (JIA), ankylosing spondylitis (AS), asthma, chronic obstructive pulmonary disease (COPD),
and the infl ammatory bowel diseases (IBDs) Crohn's disease (CD) and ulcerative colitis (UC).
- Diagnosis rates: diagnosed prevalence of select immune/infl ammatory diseases based on Decision
Resources' epidemiology.
- Current and future approaches: indication-specific modalities, challenges, opportunities, identified
and posited biomarkers, published research results.
- Dealmaking: Select deals for diagnostics and biomarkers, indication focus of dealmaking, classifications
of dealmaking companies.
Please note, the PDF e-mail from publisher version of this report is for a global site license.
|
- Executive Summary
- Strategic Considerations
- Stakeholder Implications
- Introduction
- Untapped Opportunity for Immune and Inflammatory Biomarkers
- Diagnosing and Monitoring Immune and Inflammatory Diseases
- Arthritic Conditions
- Rheumatoid Arthritis
- Juvenile Idiopathic Arthritis
- Ankylosing Spondylitis
- Systemic Lupus Erythematosus
- Pulmonary and Respiratory Conditions
- Asthma
- Chronic Obstructive Pulmonary Disease
- Inflammatory Bowel Disease
- Crohn’s Disease
- Ulcerative Colitis
- Industry Trailblazers Advancing Biomarker Research and Product Development
- Musculoskeletal Immune/Inflammatory Biomarker/Diagnostic Deals
- General Immune/Inflammatory Biomarker/Diagnostic Deals
- Respiratory Immune/Inflammatory Biomarker/Diagnostic Deals
- Strategic Considerations
- Major Breakthroughs Are Needed
- Consider the Value of Initiatives to Increase Awareness and Physician Education
- Ability to Predict Response to Therapy Would Be a Game Changer
- Tables
- 1. Immune and Inflammatory Diseases Covered in This Report and Select Associated Biomarkers
- 2. Lupus Foundation of America’s Top Ten Advances for Systemic Lupus Erythematosus in 2008
- 3. Potential Biomarkers of Asthma and Chronic Obstructive Pulmonary Disease
- 4. Select Companies Focusing on Advancing Biomarker Opportunities in Immune and Inflammatory Diseases
- Figures
- 1. Overall and Diagnosed Prevalence of Select Immune and Inflammatory Diseases in the United States, 2008
- 2. Pathological Changes in the Joints of Patients with Rheumatoid Arthritis
- 3. Rheumatologist-Estimated Percentage of Ankylosing Spondylitis Patients with Common Ankylosing Spondylitis Symptoms
- 4. Comorbidities Associated with COPD
- 5. Percentage of Immune/Inflammatory Biomarker/Diagnostic Deals by Deal Focus
- 6. Percentage of Immune/Inflammatory Biomarker/Diagnostic Deals by Therapeutic Area
- 7. Percentage of Companies Involved in Immune/Inflammatory Biomarker/Diagnostic Deals by Company Type
Share this report
Other tasks Free Alert Me service Receive bi-weekly email alerts on new market research Sign Up Today!
|
